EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Colchicine and cardiovascular events: An updated meta‐analysis of published randomized controlled trials

Sining Xie, Federica Galimberti, Elena Olmastroni, Alberico L. Catapano, Manuela Casula

Journal of Internal Medicine · 2025-12 · 298 (6) · 711-717

DOI: 10.1111/joim.20107 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Colchicine shows promise in reducing cardiovascular risk, but a recent study raised the question whether this is really the case. We conducted a meta‐analysis of randomized controlled trials (RCTs) to assess its impact on cardiovascular outcomes in secondary prevention. Methods We systematically searched major databases up to March 2025 for RCTs comparing colchicine to placebo over a treatment duration of ≥12 months, reporting major adverse cardiovascular events (MACEs). Both fixed‐ and random‐effects models were used to compute pooled risk ratios (RRs) and 95% confidence intervals. Results Six RCTs comprising 21,774 patients were included. Colchicine significantly reduced the risk of MACEs (RR 0.74 [0.60–0.92]) and specific components of primary outcome (myocardial infarction, RR 0.85 [0.73–0.98]; stroke, RR 0.79 [0.65–0.95]), with no significant effect on cardiac death and revascularization. Conclusion These results support the efficacy of low‐dose colchicine in reducing MACEs when added to standard care for at least 12 months.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →